Ortho Dermatologics announced in August that it resubmitted a new drug application to the FDA for DUOBRIITM1, a lotion for the treatment of plaque psoriasis.
Treatments for Plaque Psoriasis
The prevalence of psoriatic arthritis in patients with psoriasis worldwide appears to be around 20 percent, shows a meta-analysis published in JAAD.
A JAMA Dermatology study shows that adherence to a Mediterranean diet high in anti-inflammatory nutrients may lessen psoriasis severity.
As dermatologists become increasingly aware of comorbidities associated with psoriasis, questions of associated malignancy risk remain. Dr. Megan Noe emphasizes the need for skin cancer checks.
Ustekinumab has a higher drug survival rate than adalimumab, etanercept and infliximab, confirms a study of plaque psoriasis patients published in the Journal of Cutaneous Medicine and Surgery.
For psoriasis in difficult locations including the scalp, palms and soles, guselkumab outperformed adalimumab and placebo, shows a study published online in JAMA Dermatology.
This is the first time an IL-23 blocking drug has been shown to improve signs and symptoms of psoriatic arthritis.
A new study advises selecting biologic therapies for psoriasis based on individual factors such as patients' comorbidities, preferences and clinical situation, as well as the advantages and disadvantages of particular biologic treatments.
Adalimumab may be effective for plaque psoriasis, but not heart disease and other inflammatory conditions associated with the condition. This study confirms that the inflammatory process is unique and that one treatment may not apply to other inflammatory conditions.
Belgian pharmaceutical firm UCB has entered the immunodermatology field in the U.S. market.